Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., Vanderbilt University 1973
• 

  Previous Appointments & Affiliations

  • Professor of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Clinical Science Departments 2008 - 2013
  • Associate Professor of Psychiatry and Behavioral Sciences with Tenure, Psychiatry & Behavioral Sciences, Clinical Science Departments 1998 - 2008
  • Associate Professor of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Clinical Science Departments 1989 - 1998
• Research
• 

  Selected Grants

  • 1/2 A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS awarded by National Institutes of Health 2009 - 2016
  • Metabolomic Signatures and Biomarkers for Schizophrenia awarded by National Institutes of Health 2010 - 2013
  • Whole-genome sequencing for rare highly penetrant gene variants in schizophrenia awarded by National Institutes of Health 2009 - 2013
  • Whole-genome sequencing for rare highly penetrant gene variants in schizophrenia awarded by National Institutes of Health 2009 - 2013
  • Schizophenia Liability Genes among African-Americans awarded by National Institutes of Health 2002 - 2008
  • Same awarded by National Institutes of Health 1997 - 1999
  • Drive To Smoke And Dopamine Blockade awarded by National Institutes of Health 1994 - 1997
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • McEvoy, Joseph P., Matthew Byerly, Robert M. Hamer, Rosalie Dominik, Marvin S. Swartz, Robert A. Rosenheck, Neepa Ray, et al. “Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.” Jama 311, no. 19 (May 21, 2014): 1978–87. https://doi.org/10.1001/jama.2014.4310.
       Full Text  Link to Item
    • Jarskog, L Fredrik, Robert M. Hamer, Diane J. Catellier, Dawn D. Stewart, Lisa Lavange, Neepa Ray, Lauren H. Golden, Jeffrey A. Lieberman, T Scott Stroup, and T Scott METS Investigators. “Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.” Am J Psychiatry 170, no. 9 (September 2013): 1032–40. https://doi.org/10.1176/appi.ajp.2013.12010127.
       Full Text  Link to Item
    • Goff, Donald C., Joseph P. McEvoy, Leslie Citrome, Arnold W. Mech, Juan R. Bustillo, Roberto Gil, Peter Buckley, Theo C. Manschreck, Eric D. Achtyes, and Eric A. Macklin. “High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.” J Clin Psychopharmacol 33, no. 4 (August 2013): 485–90. https://doi.org/10.1097/JCP.0b013e3182977308.
       Full Text  Link to Item
    • McEvoy, J., R. A. Baillie, H. Zhu, P. Buckley, M. S. Keshavan, H. A. Nasrallah, G. G. Dougherty, J. K. Yao, and R. Kaddurah-Daouk. “Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics.” Plos One 8, no. 7 (July 24, 2013). https://doi.org/10.1371/journal.pone.0068717.
       Full Text
    • Jarskog, L Fredrik, Zhengchao Dong, Alayar Kangarlu, Tiziano Colibazzi, Ragy R. Girgis, Lawrence S. Kegeles, Deanna M. Barch, et al. “Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.” Neuropsychopharmacology 38, no. 7 (June 2013): 1245–52. https://doi.org/10.1038/npp.2013.23.
       Full Text  Link to Item
    • Stroup, T Scott, Matthew J. Byerly, Henry A. Nasrallah, Neepa Ray, Ahsan Y. Khan, J Steven Lamberti, Ira D. Glick, Richard M. Steinbook, Joseph P. McEvoy, and Robert M. Hamer. “Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.” Schizophr Res 146, no. 1–3 (May 2013): 190–95. https://doi.org/10.1016/j.schres.2013.01.013.
       Full Text  Link to Item
    • Watson, A. M. M., K. M. Prasad, L. Klei, J. A. Wood, R. H. Yolken, R. C. Gur, L. D. Bradford, et al. “Persistent infection with neurotropic herpes viruses and cognitive impairment.” Psychol Med 43, no. 5 (May 2013): 1023–31. https://doi.org/10.1017/S003329171200195X.
       Full Text  Link to Item
    • Wiener, Howard, Lambertus Klei, Monica Calkins, Joel Wood, Vishwajit Nimgaonkar, Ruben Gur, L DiAnne Bradford, et al. “Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects.” Schizophr Bull 39, no. 2 (March 2013): 464–71. https://doi.org/10.1093/schbul/sbr161.
       Full Text  Link to Item
    • McEvoy, Joseph P., Leslie Citrome, David Hernandez, Josephine Cucchiaro, Jay Hsu, Andrei Pikalov, and Antony Loebel. “Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.” J Clin Psychiatry 74, no. 2 (February 2013): 170–79. https://doi.org/10.4088/JCP.12m07992.
       Full Text  Link to Item
    • Citrome, L., P. J. Weiden, J. P. McEvoy, C. U. Correll, J. Cucchiaro, J. Hsu, and A. Loebel. “Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.” Cns Spectrums, 2013, 1–10. https://doi.org/10.1017/S109285291300093X.
       Full Text
    • Bamne, Mikhil, Joel Wood, Kodavali Chowdari, Annie M. Watson, Cemil Celik, Hader Mansour, Lambertus Klei, et al. “Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.” Schizophr Bull 38, no. 6 (November 2012): 1149–54. https://doi.org/10.1093/schbul/sbs087.
       Full Text  Link to Item
    • Freudenreich, Oliver, and Joseph P. McEvoy. “Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.” Clin Schizophr Relat Psychoses 6, no. 3 (October 2012): 115–21. https://doi.org/10.3371/CSRP.6.3.3.
       Full Text  Link to Item
    • Nolan, J. A., J. P. McEvoy, H. G. Koenig, E. G. Hooten, K. Whetten, and C. F. Pieper. “Religious coping and quality of life among individuals living with schizophrenia.” Psychiatr Serv 63, no. 10 (October 1, 2012): 1051–54. https://doi.org/10.1176/appi.ps.201000208.
       Full Text  Link to Item
    • Kaddurah-Daouk, Rima, Joseph McEvoy, Rebecca Baillie, Hongjie Zhu, Jeffrey K Yao, Vishwajit L. Nimgaonkar, Peter F. Buckley, Matcheri S. Keshavan, Anastasia Georgiades, and Henry A. Nasrallah. “Impaired plasmalogens in patients with schizophrenia.” Psychiatry Res 198, no. 3 (August 15, 2012): 347–52. https://doi.org/10.1016/j.psychres.2012.02.019.
       Full Text  Link to Item
    • Need, Anna C., Joseph P. McEvoy, Massimo Gennarelli, Erin L. Heinzen, Dongliang Ge, Jessica M. Maia, Kevin V. Shianna, et al. “Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia.” Am J Hum Genet 91, no. 2 (August 10, 2012): 303–12. https://doi.org/10.1016/j.ajhg.2012.06.018.
       Full Text  Link to Item
    • Savage, R. M., H. W. Wiener, V. Nimgaonkar, B. Devlin, M. E. Calkins, R. E. Gur, J. O’Jile, et al. “Heritability of functioning in families with schizophrenia in relation to neurocognition.” Schizophr Res 139, no. 1–3 (August 2012): 105–9. https://doi.org/10.1016/j.schres.2012.04.015.
       Full Text  Link to Item
    • Covell, Nancy H., Joseph P. McEvoy, Nina R. Schooler, T Scott Stroup, Carlos T. Jackson, Ingrid A. Rojas, Susan M. Essock, and Susan M. Schizophrenia Trials Network. “Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.” J Clin Psychiatry 73, no. 5 (May 2012): 669–75. https://doi.org/10.4088/JCP.11m07074.
       Full Text  Link to Item
    • Javitt, Daniel C., Robert W. Buchanan, Richard S. E. Keefe, Robert Kern, Robert P. McMahon, Michael F. Green, Jeffrey Lieberman, et al. “Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.” Schizophr Res 136, no. 1–3 (April 2012): 25–31. https://doi.org/10.1016/j.schres.2011.11.001.
       Full Text  Link to Item
    • Yao, Jeffrey K., Ruth Condray, George G. Dougherty, Matcheri S. Keshavan, Debra M. Montrose, Wayne R. Matson, Joseph McEvoy, Rima Kaddurah-Daouk, and Ravinder D. Reddy. “Associations between purine metabolites and clinical symptoms in schizophrenia.” Plos One 7, no. 8 (2012): e42165. https://doi.org/10.1371/journal.pone.0042165.
       Full Text  Link to Item
    • Greenberg, Greg, Robert A. Rosenheck, Steven K. Erickson, Rani A. Desai, Elina A. Stefanovics, Marvin Swartz, Richard S. E. Keefe, Joe McEvoy, T Scott Stroup, and T Scott CATIE Investigators. “Criminal justice system involvement among people with schizophrenia.” Community Ment Health J 47, no. 6 (December 2011): 727–36. https://doi.org/10.1007/s10597-010-9362-9.
       Full Text  Link to Item
    • Kerfoot, Karin E., Robert A. Rosenheck, Ismene L. Petrakis, Marvin S. Swartz, Richard S. E. Keefe, Joseph P. McEvoy, T Scott Stroup, and T Scott CATIE Investigators. “Substance use and schizophrenia: adverse correlates in the CATIE study sample.” Schizophr Res 132, no. 2–3 (November 2011): 177–82. https://doi.org/10.1016/j.schres.2011.07.032.
       Full Text  Link to Item
    • Stroup, T Scott, Joseph P. McEvoy, Kimberly D. Ring, Robert H. Hamer, Lisa M. LaVange, Marvin S. Swartz, Robert A. Rosenheck, et al. “A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).” Am J Psychiatry 168, no. 9 (September 2011): 947–56. https://doi.org/10.1176/appi.ajp.2011.10111609.
       Full Text  Link to Item
    • Stroup, T Scott, Paul S. Appelbaum, Hongbin Gu, Spencer Hays, Marvin S. Swartz, Richard S. E. Keefe, Scott Y. Kim, et al. “Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.” Schizophr Res 130, no. 1–3 (August 2011): 47–52. https://doi.org/10.1016/j.schres.2011.04.012.
       Full Text  Link to Item
    • Condray, Ruth, George G. Dougherty, Matcheri S. Keshavan, Ravinder D. Reddy, Gretchen L. Haas, Debra M. Montrose, Wayne R. Matson, Joseph McEvoy, Rima Kaddurah-Daouk, and Jeffrey K. Yao. “3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.” Int J Neuropsychopharmacol 14, no. 6 (July 2011): 756–67. https://doi.org/10.1017/S1461145710001689.
       Full Text  Link to Item
    • Essock, Susan M., Nina R. Schooler, T Scott Stroup, Joseph P. McEvoy, Ingrid Rojas, Carlos Jackson, Nancy H. Covell, and Nancy H. Schizophrenia Trials Network. “Effectiveness of switching from antipsychotic polypharmacy to monotherapy.” Am J Psychiatry 168, no. 7 (July 2011): 702–8. https://doi.org/10.1176/appi.ajp.2011.10060908.
       Full Text  Link to Item
    • Stauffer, Virginia L., Michael Case, Bruce J. Kinon, Robert Conley, Haya Ascher-Svanum, Sara Kollack-Walker, John Kane, Joseph McEvoy, and Jeffrey Lieberman. “Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.” Psychiatry Res 187, no. 1–2 (May 15, 2011): 42–48. https://doi.org/10.1016/j.psychres.2010.11.017.
       Full Text  Link to Item
    • McEvoy, Joseph P., and Oliver Freudenreich. “Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking.” Evid Based Ment Health 14, no. 2 (May 2011): 53. https://doi.org/10.1136/ebmh.14.2.53.
       Full Text  Link to Item
    • Hermes, Eric, Henry Nasrallah, Vicki Davis, Jonathan Meyer, Joseph McEvoy, Donald Goff, Sonia Davis, et al. “The association between weight change and symptom reduction in the CATIE schizophrenia trial.” Schizophr Res 128, no. 1–3 (May 2011): 166–70. https://doi.org/10.1016/j.schres.2011.01.022.
       Full Text  Link to Item
    • Adkins, D. E., K. Aberg, J. L. McClay, J. Bukszár, Z. Zhao, P. Jia, T. S. Stroup, et al. “Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.” Mol Psychiatry 16, no. 3 (March 2011): 321–32. https://doi.org/10.1038/mp.2010.14.
       Full Text  Link to Item
    • Caroff, Stanley N., Vicki G. Davis, Del D. Miller, Sonia M. Davis, Robert A. Rosenheck, Joseph P. McEvoy, E Cabrina Campbell, et al. “Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.” J Clin Psychiatry 72, no. 3 (March 2011): 295–303. https://doi.org/10.4088/JCP.09m05793yel.
       Full Text  Link to Item
    • Buchanan, Robert W., Richard S. E. Keefe, Jeffrey A. Lieberman, Deanna M. Barch, John G. Csernansky, Donald C. Goff, James M. Gold, et al. “A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.” Biol Psychiatry 69, no. 5 (March 1, 2011): 442–49. https://doi.org/10.1016/j.biopsych.2010.09.052.
       Full Text  Link to Item
    • McClay, Joseph L., Daniel E. Adkins, Karolina Aberg, Jozsef Bukszár, Amit N. Khachane, Richard S. E. Keefe, Diana O. Perkins, et al. “Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.” Neuropsychopharmacology 36, no. 3 (February 2011): 616–26. https://doi.org/10.1038/npp.2010.193.
       Full Text  Link to Item
    • Addington, Donald E., Somaia Mohamed, Robert A. Rosenheck, Sonia M. Davis, Thomas Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, and Jeffrey A. Lieberman. “Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.” J Clin Psychiatry 72, no. 1 (January 2011): 75–80. https://doi.org/10.4088/JCP.09m05258gre.
       Full Text  Link to Item
    • Cascella, Nicola G., Debra Kryszak, Bushra Bhatti, Patricia Gregory, Deanna L. Kelly, Joseph P. Mc Evoy, Alessio Fasano, and William W. Eaton. “Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.” Schizophr Bull 37, no. 1 (January 2011): 94–100. https://doi.org/10.1093/schbul/sbp055.
       Full Text  Link to Item
    • Covell, N. H., J. P. McEvoy, T. S. T. Stroup, N. R. Schooler, and S. M. Essock. “Response to Baandrup letter.” American Journal of Psychiatry 168, no. 10 (2011): 1117-. https://doi.org/10.1176/appi.ajp.2011.11050751r.
       Full Text
    • Yao, J. K., G. G. Dougherty, R. D. Reddy, M. S. Keshavan, D. M. Montrose, W. R. Matson, S. Rozen, R. R. Krishnan, J. McEvoy, and R. Kaddurah-Daouk. “Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.” Mol Psychiatry 15, no. 9 (September 2010): 938–53. https://doi.org/10.1038/mp.2009.33.
       Full Text  Link to Item
    • Yao, Jeffrey K., George G. Dougherty, Ravinder D. Reddy, Matcheri S. Keshavan, Debra M. Montrose, Wayne R. Matson, Joseph McEvoy, and Rima Kaddurah-Daouk. “Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.” Plos One 5, no. 3 (March 3, 2010): e9508. https://doi.org/10.1371/journal.pone.0009508.
       Full Text  Open Access Copy  Link to Item
    • McEvoy, Joseph P., Daniel Zigman, and Howard C. Margolese. “First- and second-generation antipsychotics.” Can J Psychiatry 55, no. 3 (March 2010): 144–48. https://doi.org/10.1177/070674371005500305.
       Full Text  Link to Item
    • Tsai, Huei-Ting, Stanley N. Caroff, Del D. Miller, Joseph McEvoy, Jeffrey A. Lieberman, Kari E. North, T Scott Stroup, and Patrick F. Sullivan. “A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.” Am J Med Genet B Neuropsychiatr Genet 153B, no. 1 (January 5, 2010): 336–40. https://doi.org/10.1002/ajmg.b.30981.
       Full Text  Link to Item
    • Meyer, Jonathan M., Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T Scott Stroup, and Jeffrey A. Lieberman. “Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.” Biol Psychiatry 66, no. 11 (December 1, 2009): 1013–22. https://doi.org/10.1016/j.biopsych.2009.06.005.
       Full Text  Link to Item
    • Rosenheck, Robert A., Vicki G. Davis, Sonia M. Davis, Scott Stroup, Joseph McEvoy, Marvin Swartz, and Jeffrey Lieberman. “Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.” Schizophr Res 113, no. 1 (August 2009): 12–18. https://doi.org/10.1016/j.schres.2009.06.002.
       Full Text  Link to Item
    • Need, Anna C., Richard S. E. Keefe, Dongliang Ge, Iris Grossman, Sam Dickson, Joseph P. McEvoy, and David B. Goldstein. “Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.” Eur J Hum Genet 17, no. 7 (July 2009): 946–57. https://doi.org/10.1038/ejhg.2008.264.
       Full Text  Link to Item
    • Talkowski, Michael E., Lora McClain, Trina Allen, L Dianne Bradford, Monica Calkins, Neil Edwards, Lyudmila Georgieva, et al. “Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samples.” Am J Med Genet B Neuropsychiatr Genet 150B, no. 4 (June 5, 2009): 560–69. https://doi.org/10.1002/ajmg.b.30862.
       Full Text  Link to Item
    • Patel, Jayendra K., Peter F. Buckley, Sandra Woolson, Robert M. Hamer, Joseph P. McEvoy, Diana O. Perkins, Jeffrey A. Lieberman, and Jeffrey A. CAFE Investigators. “Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.” Schizophr Res 111, no. 1–3 (June 2009): 9–16. https://doi.org/10.1016/j.schres.2009.03.025.
       Full Text  Link to Item
    • Thompson, Paul M., George Bartzokis, Kiralee M. Hayashi, Andrea D. Klunder, Po H. Lu, Nancy Edwards, Michael S. Hong, et al. “Time-lapse mapping of cortical changes in schizophrenia with different treatments.” Cereb Cortex 19, no. 5 (May 2009): 1107–23. https://doi.org/10.1093/cercor/bhn152.
       Full Text  Link to Item
    • Wiener, H. W., L. Klei, M. D. Irvin, R. T. Perry, M. H. Aliyu, T. B. Allen, L. D. Bradford, et al. “Linkage analysis of schizophrenia in African-American families.” Schizophr Res 109, no. 1–3 (April 2009): 70–79. https://doi.org/10.1016/j.schres.2009.02.007.
       Full Text  Link to Item
    • Mohamed, Somaia, Robert Rosenheck, Joseph McEvoy, Marvin Swartz, Scott Stroup, and Jeffrey A. Lieberman. “Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.” Schizophr Bull 35, no. 2 (March 2009): 336–46. https://doi.org/10.1093/schbul/sbn067.
       Full Text  Link to Item
    • Need, Anna C., Dongliang Ge, Michael E. Weale, Jessica Maia, Sheng Feng, Erin L. Heinzen, Kevin V. Shianna, et al. “A genome-wide investigation of SNPs and CNVs in schizophrenia.” Plos Genet 5, no. 2 (February 2009): e1000373. https://doi.org/10.1371/journal.pgen.1000373.
       Full Text  Link to Item
    • McEvoy, Joseph P. “Much ado about small differences.” World Psychiatry 8, no. 1 (February 2009): 29–30. https://doi.org/10.1002/j.2051-5545.2009.tb00202.x.
       Full Text  Link to Item
    • Lieberman, J. A., G. Tollefson, M. Tohen, A. I. Green, R. E. Gur, R. Kahn, J. McEvoy, et al. “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)).” American Journal of Psychiatry 166, no. 8 (2009): 942-.
    • McEvoy, J. P. “Much ado about small differences.” Postepy Psychiatrii I Neurologii 18, no. 2 (2009): 119–20.
    • McEvoy, J. P. “Antipsychotic Drugs,” January 1, 2009, 487–92. https://doi.org/10.1016/B978-008045046-9.00375-2.
       Full Text
    • Rosenheck, Robert A., Sonia Davis, Nancy Covell, Susan Essock, Marvin Swartz, Scott Stroup, Joseph McEvoy, and Jeffrey Lieberman. “Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.” Schizophr Res 107, no. 1 (January 2009): 22–29. https://doi.org/10.1016/j.schres.2008.09.031.
       Full Text  Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Sonia M. Davis, Marvin S. Swartz, Richard S. E. Keefe, Alexander L. Miller, Robert A. Rosenheck, John K. Hsiao, and John K. CATIE Investigators. “Results of phase 3 of the CATIE schizophrenia trial.” Schizophr Res 107, no. 1 (January 2009): 1–12. https://doi.org/10.1016/j.schres.2008.10.011.
       Full Text  Link to Item
    • Velligan, Dawn I., Peter J. Weiden, Martha Sajatovic, Jan Scott, Daniel Carpenter, Ruth Ross, John P. Docherty, and John P. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. “The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.” J Clin Psychiatry 70 Suppl 4 (2009): 1–46.
       Link to Item
    • Chwastiak, Lydia A., Robert A. Rosenheck, Joseph P. McEvoy, T Scott Stroup, Marvin S. Swartz, Sonia M. Davis, and Jeffrey A. Lieberman. “The impact of obesity on health care costs among persons with schizophrenia.” Gen Hosp Psychiatry 31, no. 1 (2009): 1–7. https://doi.org/10.1016/j.genhosppsych.2008.09.012.
       Full Text  Link to Item
    • Daumit, Gail L., Donald C. Goff, Jonathan M. Meyer, Vicki G. Davis, Henry A. Nasrallah, Joseph P. McEvoy, Robert Rosenheck, et al. “Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.” Schizophr Res 105, no. 1–3 (October 2008): 175–87. https://doi.org/10.1016/j.schres.2008.07.006.
       Full Text  Link to Item
    • Grossman, Iris, Patrick F. Sullivan, Nicole Walley, Youfang Liu, Jeffrey R. Dawson, Curtis Gumbs, Andrea Gaedigk, et al. “Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.” Genet Med 10, no. 10 (October 2008): 720–29. https://doi.org/10.1097/GIM.0b013e3181863239.
       Full Text  Link to Item
    • Miller, Del D., Stanley N. Caroff, Sonia M. Davis, Robert A. Rosenheck, Joseph P. McEvoy, Bruce L. Saltz, Silvana Riggio, et al. “Extrapyramidal side-effects of antipsychotics in a randomised trial.” Br J Psychiatry 193, no. 4 (October 2008): 279–88. https://doi.org/10.1192/bjp.bp.108.050088.
       Full Text  Link to Item
    • Meyer, Jonathan M., Vicki G. Davis, Joseph P. McEvoy, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Gail L. Daumit, et al. “Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.” Schizophr Res 103, no. 1–3 (August 2008): 104–9. https://doi.org/10.1016/j.schres.2008.04.023.
       Full Text  Link to Item
    • Swanson, Jeffrey W., Marvin S. Swartz, Richard A. Van Dorn, Jan Volavka, John Monahan, T Scott Stroup, Joseph P. McEvoy, et al. “Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.” Br J Psychiatry 193, no. 1 (July 2008): 37–43. https://doi.org/10.1192/bjp.bp.107.042630.
       Full Text  Link to Item
    • Swartz, Marvin S., T Scott Stroup, Joseph P. McEvoy, Sonia M. Davis, Robert A. Rosenheck, Richard S. E. Keefe, John K. Hsiao, and Jeffrey A. Lieberman. “What CATIE found: results from the schizophrenia trial.” Psychiatr Serv 59, no. 5 (May 2008): 500–506. https://doi.org/10.1176/ps.2008.59.5.500.
       Full Text  Link to Item
    • Meyer, Jonathan M., Vicki G. Davis, Donald C. Goff, Joseph P. McEvoy, Henry A. Nasrallah, Sonia M. Davis, Robert A. Rosenheck, et al. “Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.” Schizophr Res 101, no. 1–3 (April 2008): 273–86. https://doi.org/10.1016/j.schres.2007.12.487.
       Full Text  Link to Item
    • Resnick, Sandra G., Robert A. Rosenheck, Jose M. Canive, Cyril De Souza, T Scott Stroup, Joseph McEvoy, Sonia Davis, Richard S. E. Keefe, Marvin Swartz, and Jeffrey Lieberman. “Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.” J Behav Health Serv Res 35, no. 2 (April 2008): 215–25. https://doi.org/10.1007/s11414-007-9101-3.
       Full Text  Link to Item
    • Hill, S Kristian, John A. Sweeney, Robert M. Hamer, Richard S. E. Keefe, Diana O. Perkins, Hongbin Gu, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.” J Int Neuropsychol Soc 14, no. 2 (March 2008): 209–21. https://doi.org/10.1017/S1355617708080570.
       Full Text  Link to Item
    • Swartz, Marvin S., H Ryan Wagner, Jeffrey W. Swanson, T Scott Stroup, Joseph P. McEvoy, Fred Reimherr, Del D. Miller, et al. “The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.” Schizophr Res 100, no. 1–3 (March 2008): 39–52. https://doi.org/10.1016/j.schres.2007.11.034.
       Full Text  Link to Item
    • Daumit, G. L., D. C. Goff, J. M. Meyer, V. G. Davis, H. A. Nasrallah, J. P. McEvoy, R. Rosenheck, et al. “Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.” Schizophrenia Research, 2008.
    • Kinon, B. J., J. Volavka, V. Stauffer, S. E. Edwards, H. Liu-Seifert, L. Chen, D. H. Adams, et al. “Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study.” Journal of Clinical Psychopharmacology 28, no. 4 (2008): 392–400. https://doi.org/10.1097/JCP.0b013e31817e63a5.
       Full Text
    • McEvoy, Joseph P. “Functional outcomes in schizophrenia.” J Clin Psychiatry 69 Suppl 3 (2008): 20–24.
       Link to Item
    • McEvoy, J. P., and O. Freudenreich. “Issues in the Design and Conductance of Clinical Trials,” January 1, 2008, 75–95. https://doi.org/10.1016/B978-0-12-373861-5.00003-5.
       Full Text
    • Perkins, Diana O., Hongbin Gu, Peter J. Weiden, Joseph P. McEvoy, Robert M. Hamer, Jeffrey A. Lieberman, and Jeffrey A. Comparison of Atypicals in First Episode study group. “Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.” J Clin Psychiatry 69, no. 1 (January 2008): 106–13. https://doi.org/10.4088/jcp.v69n0114.
       Full Text  Link to Item
    • Keefe, R. S. E., J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman. “Dr. Keefe and colleagues reply.” American Journal of Psychiatry 164, no. 12 (December 1, 2007): 1911–12. https://doi.org/10.1176/appi.ajp.2007.07071086r.
       Full Text
    • McEvoy, Joseph P., David G. Daniel, William H. Carson, Robert D. McQuade, and Ronald N. Marcus. “A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.” J Psychiatr Res 41, no. 11 (December 2007): 895–905. https://doi.org/10.1016/j.jpsychires.2007.05.002.
       Full Text  Link to Item
    • Stroup, T. S., J. P. McEvoy, M. S. Swartz, R. M. Hamer, D. O. Perkins, and J. A. Lieberman. “Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study.” Clinical Schizophrenia and Related Psychoses 1, no. 1 (December 1, 2007): 69–72. https://doi.org/10.3371/CSRP.1.1.6.
       Full Text
    • Moore, Troy A., Robert W. Buchanan, Peter F. Buckley, John A. Chiles, Robert R. Conley, M Lynn Crismon, Susan M. Essock, et al. “The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.” J Clin Psychiatry 68, no. 11 (November 2007): 1751–62. https://doi.org/10.4088/jcp.v68n1115.
       Full Text  Link to Item
    • Kaddurah-Daouk, R., J. McEvoy, R. A. Baillie, D. Lee, J. K. Yao, P. M. Doraiswamy, and K. R. R. Krishnan. “Metabolomic mapping of atypical antipsychotic effects in schizophrenia.” Mol Psychiatry 12, no. 10 (October 2007): 934–45. https://doi.org/10.1038/sj.mp.4002000.
       Full Text  Link to Item
    • Keefe, Richard S. E., John A. Sweeney, Hongbin Gu, Robert M. Hamer, Diana O. Perkins, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.” Am J Psychiatry 164, no. 7 (July 2007): 1061–71. https://doi.org/10.1176/ajp.2007.164.7.1061.
       Full Text  Link to Item
    • Kim, Scott Y. H., Paul S. Appelbaum, Jeffrey Swan, T Scott Stroup, Joseph P. McEvoy, Donald C. Goff, Dilip V. Jeste, J Steven Lamberti, Adrian Leibovici, and Eric D. Caine. “Determining when impairment constitutes incapacity for informed consent in schizophrenia research.” Br J Psychiatry 191 (July 2007): 38–43. https://doi.org/10.1192/bjp.bp.106.033324.
       Full Text  Link to Item
    • McEvoy, Joseph P., Jeffrey A. Lieberman, Diana O. Perkins, Robert M. Hamer, Hongbin Gu, Arthur Lazarus, Dennis Sweitzer, Christina Olexy, Peter Weiden, and Stephen D. Strakowski. “Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.” Am J Psychiatry 164, no. 7 (July 2007): 1050–60. https://doi.org/10.1176/ajp.2007.164.7.1050.
       Full Text  Link to Item
    • Keefe, Richard S. E., Robert M. Bilder, Sonia M. Davis, Philip D. Harvey, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.” Arch Gen Psychiatry 64, no. 6 (June 2007): 633–47. https://doi.org/10.1001/archpsyc.64.6.633.
       Full Text  Link to Item
    • McEvoy, Joseph P. “The importance of early treatment of schizophrenia.” Behav Healthc 27, no. 4 (April 2007): 40–43.
       Link to Item
    • Rosenheck, Robert, Marvin Swartz, Joseph McEvoy, T Scott Stroup, Sonia Davis, Richard Se Keefe, John Hsiao, and Jeffrey Lieberman. “Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.” Expert Rev Pharmacoecon Outcomes Res 7, no. 2 (April 2007): 103–11. https://doi.org/10.1586/14737167.7.2.103.
       Full Text  Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Marvin S. Swartz, Sonia M. Davis, George A. Capuano, Robert A. Rosenheck, et al. “Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.” Am J Psychiatry 164, no. 3 (March 2007): 415–27. https://doi.org/10.1176/ajp.2007.164.3.415.
       Full Text  Link to Item
    • Swartz, Marvin S., Diana O. Perkins, T Scott Stroup, Sonia M. Davis, George Capuano, Robert A. Rosenheck, Fred Reimherr, et al. “Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.” Am J Psychiatry 164, no. 3 (March 2007): 428–36. https://doi.org/10.1176/ajp.2007.164.3.428.
       Full Text  Link to Item
    • Aliyu, M. H., M. E. Calkins, C. L. Swanson, P. D. Lyons, R. M. Savage, R. May, H. Wiener, et al. “Erratum to "Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Recruitment and assessment methods" [Schizophrenia Research 87 (1-3) (2006) 32-44] (DOI:10.1016/j.schres.2006.06.027).” Schizophrenia Research 90, no. 1–3 (February 1, 2007): 369. https://doi.org/10.1016/j.schres.2006.11.002.
       Full Text
    • McEvoy, Joseph P. “The costs of schizophrenia.” J Clin Psychiatry 68 Suppl 14 (2007): 4–7.
       Link to Item
    • Rosenheck, R., T. S. Stroup, M. Swartz, J. McEvoy, S. M. Davis, R. S. E. Keefe, J. K. Hsiao, and J. Lieberman. “Dr. Rosenheck and colleagues reply [2].” American Journal of Psychiatry 164, no. 4 (January 1, 2007): 678–80. https://doi.org/10.1176/ajp.2007.164.4.678a.
       Full Text
    • Freudenreich, Oliver, Joseph P. McEvoy, Donald C. Goff, and Gregory L. Fricchione. “Catatonic coma with profound bradycardia.” Psychosomatics 48, no. 1 (2007): 74–78. https://doi.org/10.1176/appi.psy.48.1.74.
       Full Text  Link to Item
    • Rosenheck, Robert A., Douglas L. Leslie, Jody Sindelar, Edward A. Miller, Haiqun Lin, T Scott Stroup, Joseph McEvoy, et al. “Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.” Am J Psychiatry 163, no. 12 (December 2006): 2080–89. https://doi.org/10.1176/ajp.2006.163.12.2080.
       Full Text  Link to Item
    • McEvoy, Joseph P., Jackie Johnson, Diana Perkins, Jeffrey A. Lieberman, Robert M. Hamer, Richard S. E. Keefe, Mauricio Tohen, Ira D. Glick, and Tonmoy Sharma. “Insight in first-episode psychosis.” Psychol Med 36, no. 10 (October 2006): 1385–93. https://doi.org/10.1017/S0033291706007793.
       Full Text  Link to Item
    • Aliyu, Muktar H., Monica E. Calkins, Charlie L. Swanson, Paul D. Lyons, Robert M. Savage, Roberta May, Howard Wiener, et al. “Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods.” Schizophr Res 87, no. 1–3 (October 2006): 32–44. https://doi.org/10.1016/j.schres.2006.06.027.
       Full Text  Link to Item
    • Green, A. I., J. A. Lieberman, R. M. Hamer, I. D. Glick, R. E. Gur, R. S. Kahn, J. P. McEvoy, et al. “Olanzapine and haloperidol in first episode psychosis: two-year data.” Schizophr Res 86, no. 1–3 (September 2006): 234–43. https://doi.org/10.1016/j.schres.2006.06.021.
       Full Text  Link to Item
    • Keefe, Richard S. E., Robert M. Bilder, Philip D. Harvey, Sonia M. Davis, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Baseline neurocognitive deficits in the CATIE schizophrenia trial.” Neuropsychopharmacology 31, no. 9 (September 2006): 2033–46. https://doi.org/10.1038/sj.npp.1301072.
       Full Text  Link to Item
    • Nasrallah, Henry A., Jonathan M. Meyer, Donald C. Goff, Joseph P. McEvoy, Sonia M. Davis, T Scott Stroup, and Jeffrey A. Lieberman. “Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.” Schizophr Res 86, no. 1–3 (September 2006): 15–22. https://doi.org/10.1016/j.schres.2006.06.026.
       Full Text  Link to Item
    • Chwastiak, Lydia A., Robert A. Rosenheck, Joseph P. McEvoy, Richard S. Keefe, Marvin S. Swartz, and Jeffrey A. Lieberman. “Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.” Psychiatr Serv 57, no. 8 (August 2006): 1102–9. https://doi.org/10.1176/ps.2006.57.8.1102.
       Full Text  Link to Item
    • Swartz, Marvin S., H Ryan Wagner, Jeffrey W. Swanson, T Scott Stroup, Joseph P. McEvoy, Mark McGee, Del D. Miller, et al. “Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.” Psychiatr Serv 57, no. 8 (August 2006): 1110–16. https://doi.org/10.1176/ps.2006.57.8.1110.
       Full Text  Link to Item
    • McEvoy, Joseph P. “An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.” Cns Spectr 11, no. 7 Suppl 7 (July 2006): 4–8. https://doi.org/10.1017/s1092852900026626.
       Full Text  Link to Item
    • Swanson, Jeffrey W., Marvin S. Swartz, Richard A. Van Dorn, Eric B. Elbogen, H Ryan Wagner, Robert A. Rosenheck, T Scott Stroup, Joseph P. McEvoy, and Jeffrey A. Lieberman. “A national study of violent behavior in persons with schizophrenia.” Arch Gen Psychiatry 63, no. 5 (May 2006): 490–99. https://doi.org/10.1001/archpsyc.63.5.490.
       Full Text  Link to Item
    • McEvoy, Joseph P., Jeffrey A. Lieberman, T Scott Stroup, Sonia M. Davis, Herbert Y. Meltzer, Robert A. Rosenheck, Marvin S. Swartz, et al. “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.” Am J Psychiatry 163, no. 4 (April 2006): 600–610. https://doi.org/10.1176/ajp.2006.163.4.600.
       Full Text  Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Marvin S. Swartz, Sonia M. Davis, Robert A. Rosenheck, Diana O. Perkins, et al. “Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.” Am J Psychiatry 163, no. 4 (April 2006): 611–22. https://doi.org/10.1176/ajp.2006.163.4.611.
       Full Text  Link to Item
    • Lieberman, J. A., T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. E. Keefe, et al. “Dr. Lieberman and Colleagues reply [17].” American Journal of Psychiatry 163, no. 3 (March 1, 2006): 555–56.
    • Perkins, Diana O., Jacqueline L. Johnson, Robert M. Hamer, Robert B. Zipursky, Richard S. Keefe, Franca Centorrhino, Alan I. Green, et al. “Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.” Schizophr Res 83, no. 1 (March 2006): 53–63. https://doi.org/10.1016/j.schres.2005.10.016.
       Full Text  Link to Item
    • Rosenheck, Robert, Douglas Leslie, Richard Keefe, Joseph McEvoy, Marvin Swartz, Diana Perkins, Scott Stroup, John K. Hsiao, Jeffrey Lieberman, and Jeffrey CATIE Study Investigators Group. “Barriers to employment for people with schizophrenia.” Am J Psychiatry 163, no. 3 (March 2006): 411–17. https://doi.org/10.1176/appi.ajp.163.3.411.
       Full Text  Link to Item
    • Swartz, Marvin S., H Ryan Wagner, Jeffrey W. Swanson, T Scott Stroup, Joseph P. McEvoy, Jose M. Canive, Del D. Miller, et al. “Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.” J Nerv Ment Dis 194, no. 3 (March 2006): 164–72. https://doi.org/10.1097/01.nmd.0000202575.79453.6e.
       Full Text  Link to Item
    • Yang, Yen Kuang, Wei Jen Yao, Joseph P. McEvoy, Ching Lin Chu, I Hui Lee, Po See Chen, Tzung Lieh Yeh, and Nan Tsing Chiu. “Striatal dopamine D2/D3 receptor availability in male smokers.” Psychiatry Res 146, no. 1 (January 30, 2006): 87–90. https://doi.org/10.1016/j.pscychresns.2005.09.008.
       Full Text  Link to Item
    • McEvoy, Joseph P. “Risks versus benefits of different types of long-acting injectable antipsychotics.” J Clin Psychiatry 67 Suppl 5 (2006): 15–18.
       Link to Item
    • McEvoy, Joseph P., Jonathan M. Meyer, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Lisa Sullivan, Herbert Y. Meltzer, John Hsiao, T. Scott Stroup, and Jeffrey A. Lieberman. “Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.” Schizophr Res 80, no. 1 (December 1, 2005): 19–32. https://doi.org/10.1016/j.schres.2005.07.014.
       Full Text  Link to Item
    • Meyer, Jonathan M., Henry A. Nasrallah, Joseph P. McEvoy, Donald C. Goff, Sonia M. Davis, Miranda Chakos, Jayendra K. Patel, Richard S. E. Keefe, T Scott Stroup, and Jeffrey A. Lieberman. “The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.” Schizophr Res 80, no. 1 (December 1, 2005): 9–18. https://doi.org/10.1016/j.schres.2005.07.015.
       Full Text  Link to Item
    • Miller, Del D., Joseph P. McEvoy, Sonia M. Davis, Stanley N. Caroff, Bruce L. Saltz, Miranda H. Chakos, Marvin S. Swartz, et al. “Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.” Schizophr Res 80, no. 1 (December 1, 2005): 33–43. https://doi.org/10.1016/j.schres.2005.07.034.
       Full Text  Link to Item
    • Rosenheck, Robert, Scott Stroup, Richard S. E. Keefe, Joseph McEvoy, Marvin Swartz, Diana Perkins, John Hsiao, Martha Shumway, and Jeffrey Lieberman. “Measuring outcome priorities and preferences in people with schizophrenia.” Br J Psychiatry 187 (December 2005): 529–36. https://doi.org/10.1192/bjp.187.6.529.
       Full Text  Link to Item
    • Stroup, Scott, Paul Appelbaum, Marvin Swartz, Mukesh Patel, Sonia Davis, Dilip Jeste, Scott Kim, et al. “Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.” Schizophr Res 80, no. 1 (December 1, 2005): 1–8. https://doi.org/10.1016/j.schres.2005.08.007.
       Full Text  Link to Item
    • Zipursky, Robert B., Hongbin Gu, Alan I. Green, Diana O. Perkins, Mauricio F. Tohen, Joseph P. McEvoy, Stephen M. Strakowski, et al. “Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.” Br J Psychiatry 187 (December 2005): 537–43. https://doi.org/10.1192/bjp.187.6.537.
       Full Text  Link to Item
    • Strakowski, Stephen M., Jacqueline L. Johnson, Melissa P. Delbello, Robert M. Hamer, Alan I. Green, Mauricio Tohen, Jeffrey A. Lieberman, Ira Glick, Jayendra K. Patel, and Jayendra K. HGDH Research Group. “Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.” Schizophr Res 78, no. 2–3 (October 15, 2005): 161–69. https://doi.org/10.1016/j.schres.2005.04.017.
       Full Text  Link to Item
    • Müller, Daniel J., Vincenzo De Luca, Tricia Sicard, Nicole King, Rudi Hwang, Jan Volavka, Pal Czobor, et al. “Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.” Eur Neuropsychopharmacol 15, no. 5 (October 2005): 525–31. https://doi.org/10.1016/j.euroneuro.2005.02.001.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., T Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, Robert A. Rosenheck, Diana O. Perkins, Richard S. E. Keefe, et al. “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.” N Engl J Med 353, no. 12 (September 22, 2005): 1209–23. https://doi.org/10.1056/NEJMoa051688.
       Full Text  Link to Item
    • Müller, Daniel J., Tim A. Klempan, Vincenzo De Luca, Tricia Sicard, Jan Volavka, Pal Czobor, Brian B. Sheitman, et al. “The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.” Neurosci Lett 379, no. 2 (May 6, 2005): 81–89. https://doi.org/10.1016/j.neulet.2004.12.037.
       Full Text  Link to Item
    • Kinghorn, Warren A., and Joseph P. McEvoy. “Aripiprazole: pharmacology, efficacy, safety and tolerability.” Expert Rev Neurother 5, no. 3 (May 2005): 297–307. https://doi.org/10.1586/14737175.5.3.297.
       Full Text  Link to Item
    • De Luca, Vincenzo, John B. Vincent, Daniel J. Müller, Rudi Hwang, Takahiro Shinkai, Jan Volavka, Pal Czobor, et al. “Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.” Pharmacol Res 51, no. 4 (April 2005): 381–84. https://doi.org/10.1016/j.phrs.2004.10.013.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., Gary D. Tollefson, Cecil Charles, Robert Zipursky, Tonmoy Sharma, Rene S. Kahn, Richard S. E. Keefe, et al. “Antipsychotic drug effects on brain morphology in first-episode psychosis.” Arch Gen Psychiatry 62, no. 4 (April 2005): 361–70. https://doi.org/10.1001/archpsyc.62.4.361.
       Full Text  Link to Item
    • Goff, D. C., L. M. Sullivan, J. P. McEvoy, J. M. Meyer, H. A. Nasrallah, G. L. Daumit, S. Lamberti, et al. “A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.” Schizophrenia Research 80, no. 1 (2005): 45–53. https://doi.org/10.1016/j.schres.2005.08.010.
       Full Text
    • Lauriello, John, Joseph P. McEvoy, Stephen Rodriguez, Cynthia A. Bossie, and Robert A. Lasser. “Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.” Schizophr Res 72, no. 2–3 (January 1, 2005): 249–58. https://doi.org/10.1016/j.schres.2004.05.006.
       Full Text  Link to Item
    • Nolan, Karen A., Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie L. Citrome, Joseph McEvoy, and Jeffrey A. Lieberman. “Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.” J Psychiatr Res 39, no. 1 (January 2005): 109–15. https://doi.org/10.1016/j.jpsychires.2004.04.010.
       Full Text  Link to Item
    • Volavka, J., K. A. Nolan, L. Kline, P. Czobor, L. Citrome, B. Sheitman, J. P. Lindenmayer, J. McEvoy, and J. A. Lieberman. “Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3].” Schizophrenia Research 76, no. 1 (2005): 127–29. https://doi.org/10.1016/j.schres.2004.11.007.
       Full Text
    • Perkins, Diana, Jeffrey Lieberman, Hongbin Gu, Mauricio Tohen, Joseph McEvoy, Alan Green, Robert Zipursky, et al. “Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.” Br J Psychiatry 185 (July 2004): 18–24. https://doi.org/10.1192/bjp.185.1.18.
       Full Text  Link to Item
    • Volavka, Jan, James L. Kennedy, Xingqun Ni, Pal Czobor, Karen Nolan, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph McEvoy, and Jeffrey A. Lieberman. “COMT158 polymorphism and hostility.” Am J Med Genet B Neuropsychiatr Genet 127B, no. 1 (May 15, 2004): 28–29. https://doi.org/10.1002/ajmg.b.20149.
       Full Text  Link to Item
    • Lindenmayer, Jean-Pierre, Pal Czobor, Jan Volavka, Jeffrey A. Lieberman, Leslie Citrome, Brian Sheitman, Joseph P. McEvoy, Thomas B. Cooper, and Miranda Chakos. “Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.” J Clin Psychiatry 65, no. 4 (April 2004): 551–56. https://doi.org/10.4088/jcp.v65n0416.
       Full Text  Link to Item
    • Weisler, Richard H., Amir H. Kalali, Terence A. Ketter, and Terence A. SPD417 Study Group. “A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.” J Clin Psychiatry 65, no. 4 (April 2004): 478–84. https://doi.org/10.4088/jcp.v65n0405.
       Full Text  Link to Item
    • Miller, Alexander L., Catherine S. Hall, Robert W. Buchanan, Peter F. Buckley, John A. Chiles, Robert R. Conley, M Lynn Crismon, et al. “The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.” J Clin Psychiatry 65, no. 4 (April 2004): 500–508. https://doi.org/10.4088/jcp.v65n0408.
       Full Text  Link to Item
    • Stroup, T Scott, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Revised PORT recommendations.” Schizophr Bull 30, no. 3 (2004): 609–11. https://doi.org/10.1093/oxfordjournals.schbul.a007106.
       Full Text  Link to Item
    • Volavka, J., P. Czobor, K. Nolan, B. Sheitman, J. P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, and J. A. Lieberman. “Overt Aggression and Psychotic Symptoms in Patients with Schizophrenia Treated with Clozapine, Olanzapine, Risperidone, or Haloperidol.” Journal of Clinical Psychopharmacology 24, no. 2 (2004): 225–28. https://doi.org/10.1097/01.jcp.0000117424.05703.29.
       Full Text
    • Volavka, Jan, Pal Czobor, Thomas B. Cooper, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.” J Clin Psychiatry 65, no. 1 (January 2004): 57–61. https://doi.org/10.4088/jcp.v65n0109.
       Full Text  Link to Item
    • Keefe, Richard S. E., Margaret P. Poe, Joseph P. McEvoy, and Adam Vaughan. “Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.” Psychopharmacology (Berl) 169, no. 3–4 (September 2003): 383–89. https://doi.org/10.1007/s00213-003-1476-0.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., Gary Tollefson, Mauricio Tohen, Alan I. Green, Raquel E. Gur, Rene Kahn, Joseph McEvoy, et al. “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.” Am J Psychiatry 160, no. 8 (August 2003): 1396–1404. https://doi.org/10.1176/appi.ajp.160.8.1396.
       Full Text  Link to Item
    • McEvoy, J. P., and T. B. Allen. “Substance abuse (including nicotine) in schizophrenic patients.” Current Opinion in Psychiatry 16, no. 2 (March 1, 2003): 199–205. https://doi.org/10.1097/00001504-200303000-00010.
       Full Text
    • Yang, Yen Kuang, Joseph P. McEvoy, William H. Wilson, Edward D. Levin, and Jed E. Rose. “Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia.” Schizophr Res 60, no. 1 (March 1, 2003): 9–12. https://doi.org/10.1016/s0920-9964(02)00208-6.
       Full Text  Link to Item
    • Lindenmayer, Jean-Pierre, Pal Czobor, Jan Volavka, Leslie Citrome, Brian Sheitman, Joseph P. McEvoy, Thomas B. Cooper, Miranda Chakos, and Jeffrey A. Lieberman. “Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.” Am J Psychiatry 160, no. 2 (February 2003): 290–96. https://doi.org/10.1176/appi.ajp.160.2.290.
       Full Text  Link to Item
    • Stroup, T Scott, Joseph P. McEvoy, Marvin S. Swartz, Matthew J. Byerly, Ira D. Glick, Jose M. Canive, Mark F. McGee, George M. Simpson, Michael C. Stevens, and Jeffrey A. Lieberman. “The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.” Schizophr Bull 29, no. 1 (2003): 15–31. https://doi.org/10.1093/oxfordjournals.schbul.a006986.
       Full Text  Link to Item
    • Swartz, Marvin S., Diana O. Perkins, T Scott Stroup, Joseph P. McEvoy, Jennifer M. Nieri, and David C. Haak. “Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.” Schizophr Bull 29, no. 1 (2003): 33–43. https://doi.org/10.1093/oxfordjournals.schbul.a006989.
       Full Text  Link to Item
    • Bilder, Robert M., Jan Volavka, Pál Czobor, Anil K. Malhotra, James L. Kennedy, Xingqun Ni, Robert S. Goldman, et al. “Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.” Biol Psychiatry 52, no. 7 (October 1, 2002): 701–7. https://doi.org/10.1016/s0006-3223(02)01416-6.
       Full Text  Link to Item
    • Yang, Yen Kuang, Leann Nelson, Lakshmi Kamaraju, William Wilson, and Joseph P. McEvoy. “Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.” Neuropsychopharmacology 27, no. 4 (October 2002): 684–86. https://doi.org/10.1016/S0893-133X(02)00325-1.
       Full Text  Link to Item
    • Lindenmayer, Jean-Pierre, Pal Czobor, Jan Volavka, Jeffrey A. Lieberman, Leslie Citrome, Brian Sheitman, Miranda Chakos, and Joseph P. McEvoy. “Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.” J Clin Psychiatry 63, no. 10 (October 2002): 931–35. https://doi.org/10.4088/jcp.v63n1011.
       Full Text  Link to Item
    • Keefe, Richard S. E., Miriam C. Arnold, Ute J. Bayen, Joseph P. McEvoy, and William H. Wilson. “Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.” Schizophr Res 57, no. 1 (September 1, 2002): 51–67. https://doi.org/10.1016/s0920-9964(01)00306-1.
       Full Text  Link to Item
    • McEvoy, Joseph P., and Trina B. Allen. “The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome.” Curr Drug Targets Cns Neurol Disord 1, no. 4 (August 2002): 433–42. https://doi.org/10.2174/1568007023339210.
       Full Text  Link to Item
    • Czobor, Pál, Jan Volavka, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph McEvoy, Thomas B. Cooper, Miranda Chakos, and Jeffrey A. Lieberman. “Antipsychotic-induced weight gain and therapeutic response: a differential association.” J Clin Psychopharmacol 22, no. 3 (June 2002): 244–51. https://doi.org/10.1097/00004714-200206000-00003.
       Full Text  Link to Item
    • Allen, T. B., and J. R. McEvoy. “Galantamine for treatment-resistant schizophrenia [3].” American Journal of Psychiatry 159, no. 7 (2002): 1244–45. https://doi.org/10.1176/appi.ajp.159.7.1244.
       Full Text
    • Bilder, R. M., R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J. P. Lindenmayer, et al. “Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.” American Journal of Psychiatry 159, no. 6 (2002): 1018–28. https://doi.org/10.1176/appi.ajp.159.6.1018.
       Full Text
    • Haan, L. D., T. V. Amelsvoort, R. M. Bilder, J. Volavka, L. Citrome, P. Czobor, M. Hoptman, et al. “Comparable dopamine 2 receptor occupancy [10] (multiple letters).” American Journal of Psychiatry 159, no. 12 (2002): 2118–19. https://doi.org/10.1176/appi.ajp.159.12.2118.
       Full Text
    • Volavka, J., P. Czobor, B. Sheitman, J. P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman. “Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.” American Journal of Psychiatry 159, no. 2 (2002): 255–62. https://doi.org/10.1176/appi.ajp.159.2.255.
       Full Text
    • Cassidy, Frederick, Joseph P. McEvoy, Yen Kuang Yang, and William H. Wilson. “Smoking and psychosis in patients with bipolar I disorder.” Compr Psychiatry 43, no. 1 (2002): 63–64. https://doi.org/10.1053/comp.2002.29847.
       Full Text  Link to Item
    • Conway, Charles R., Anna M. Bollini, Brevick G. Graham, Richard S. E. Keefe, Susan S. Schiffman, and Joseph P. McEvoy. “Sensory acuity and reasoning in delusional disorder.” Compr Psychiatry 43, no. 3 (2002): 175–78. https://doi.org/10.1053/comp.2002.32358.
       Full Text  Link to Item
    • Citrome, L., J. Volavka, P. Czobor, B. Sheitman, J. P. Lindenmayer, J. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman. “Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.” Psychiatr Serv 52, no. 11 (November 2001): 1510–14. https://doi.org/10.1176/appi.ps.52.11.1510.
       Full Text  Link to Item
    • Cassidy, F., J. P. McEvoy, Y. K. Yang, and W. H. Wilson. “Insight is greater in mixed than in pure manic episodes of bipolar I disorder.” J Nerv Ment Dis 189, no. 6 (June 2001): 398–99. https://doi.org/10.1097/00005053-200106000-00008.
       Full Text  Link to Item
    • Marx, C. E., E. McIntosh, W. H. Wilson, and J. P. McEvoy. “Mecamylamine increases cigarette smoking in psychiatric patients.” J Clin Psychopharmacol 20, no. 6 (December 2000): 706–7. https://doi.org/10.1097/00004714-200012000-00023.
       Full Text  Link to Item
    • Lieberman, J. A., R. Golden, S. Stroup, and J. McEvoy. “Drugs of the psychopharmacological revolution in clinical psychiatry.” Psychiatr Serv 51, no. 10 (October 2000): 1254–58. https://doi.org/10.1176/appi.ps.51.10.1254.
       Full Text  Link to Item
    • McEvoy, J. P. “Schirophrenia, substance misuse, and smoking.” Current Opinion in Psychiatry 13, no. 1 (January 1, 2000): 15–19. https://doi.org/10.1097/00001504-200001000-00004.
       Full Text
    • McEvoy, J. P., and M. L. Wilkinson. “The role of insight in the treatment and outcome of bipolar disorder.” Psychiatric Annals 30, no. 7 (2000): 496–98.
    • McEvoy, J. P., O. Freudenreich, and W. H. Wilson. “Smoking and therapeutic response to clozapine in patients with schizophrenia.” Biol Psychiatry 46, no. 1 (July 1, 1999): 125–29. https://doi.org/10.1016/s0006-3223(98)00377-1.
       Full Text  Link to Item
    • Hirschfeld, R. M., M. H. Allen, J. P. McEvoy, P. E. K. Jr, and J. M. Russell. “Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.” The Journal of Clinical Psychiatry 60, no. 12 (1999): 815–18.
    • McEvoy, J. P., and S. Brown. “Smoking in first-episode patients with schizophrenia [12].” American Journal of Psychiatry 156, no. 7 (1999): 1120–21.
    • McEvoy, J. P. “New treatment options to improve clinical outcomes.” Journal of Clinical Psychiatry 59, no. SUPPL. 1 (1998): 3–4.
    • Freudenreich, O., R. D. Weiner, and J. P. McEvoy. “Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.” Biol Psychiatry 42, no. 2 (July 15, 1997): 132–37. https://doi.org/10.1016/S0006-3223(96)00298-3.
       Full Text  Link to Item
    • Anton, R. F., H. R. Kranzler, J. P. McEvoy, D. H. Moak, and R. Bianca. “A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal.” Psychopharmacology 131, no. 2 (1997): 123–29. https://doi.org/10.1007/s002130050274.
       Full Text
    • Gilmore, J. H., L. F. Jarskog, J. C. Lindgren, J. P. McEvoy, and H. Xiao. “Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness.” Psychiatry Research 73, no. 1–2 (1997): 109–13. https://doi.org/10.1016/S0165-1781(97)00116-9.
       Full Text
    • Weiss, K. M., S. Hartley, D. A. Kahn, J. P. Docherty, A. Frances, J. P. McEvoy, P. J. Weiden, and D. Carpenter. “Guideline series commentary [4] (multiple letters).” Journal of Clinical Psychiatry 58, no. 10 (1997): 452–53.
    • Donnelly, C. L., J. P. McEvoy, W. H. Wilson, and N. Narasimhachari. “A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.” Biol Psychiatry 40, no. 12 (December 15, 1996): 1218–21. https://doi.org/10.1016/0006-3223(95)00650-8.
       Full Text  Link to Item
    • Chambers, R. A., J. Moore, J. P. McEvoy, and E. D. Levin. “Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia.” Neuropsychopharmacology 15, no. 6 (December 1996): 587–94. https://doi.org/10.1016/S0893-133X(96)00132-7.
       Full Text  Link to Item
    • Levin, E. D., W. Wilson, J. E. Rose, and J. McEvoy. “Nicotine-haloperidol interactions and cognitive performance in schizophrenics.” Neuropsychopharmacology 15, no. 5 (November 1996): 429–36. https://doi.org/10.1016/S0893-133X(96)00018-8.
       Full Text  Link to Item
    • Freudenreich, O., J. P. McEvoy, and T. B. Cooper. “Monitoring of clozapine blood levels in the real world [10].” Journal of Clinical Psychopharmacology 16, no. 1 (1996): 90–91. https://doi.org/10.1097/00004714-199602000-00023.
       Full Text
    • Freudenreich, O., and J. P. McEvoy. “Palinacousis after closed-head injury in a patient with schizophrenia [13].” Journal of Clinical Psychopharmacology 16, no. 1 (1996): 94-.
    • Kammen, D. P. V., J. P. McEvoy, S. D. Targum, D. Kardatzke, and T. B. Sebree. “A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.” Psychopharmacology 124, no. 1–2 (1996): 168–75. https://doi.org/10.1007/BF02245618.
       Full Text
    • McEvoy, J. P., M. Hartman, D. Gottlieb, S. Godwin, L. J. Apperson, and W. Wilson. “Common sense, insight, and neuropsychological test performance in schizophrenia patients.” Schizophr Bull 22, no. 4 (1996): 635–41. https://doi.org/10.1093/schbul/22.4.635.
       Full Text  Link to Item
    • McEvoy, J. P., and J. Lindgren. “Smoking and schizophrenia.” Drug Development Research 38, no. 3–4 (1996): 263–66. https://doi.org/10.1002/(SICI)1098-2299(199607/08)38:3/4<263::AID-DDR15>3.0.CO;2-#.
       Full Text
    • VanderZwaag, C., M. McGee, J. P. McEvoy, O. Freudenreich, W. H. Wilson, and T. B. Cooper. “Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.” American Journal of Psychiatry 153, no. 12 (1996): 1579–84.
    • Swanson, C. L., O. Freudenreich, J. P. McEvoy, L. Nelson, L. Kamaraju, and W. H. Wilson. “Insight in schizophrenia and mania.” J Nerv Ment Dis 183, no. 12 (December 1995): 752–55. https://doi.org/10.1097/00005053-199512000-00004.
       Full Text  Link to Item
    • McEvoy, J. P., O. Freudenreich, E. D. Levin, and J. E. Rose. “Haloperidol increases smoking in patients with schizophrenia.” Psychopharmacology (Berl) 119, no. 1 (May 1995): 124–26. https://doi.org/10.1007/BF02246063.
       Full Text  Link to Item
    • McEvoy, J., O. Freudenreich, M. McGee, C. VanderZwaag, E. Levin, and J. Rose. “Clozapine decreases smoking in patients with chronic schizophrenia.” Biol Psychiatry 37, no. 8 (April 15, 1995): 550–52. https://doi.org/10.1016/0006-3223(94)00365-A.
       Full Text  Link to Item
    • Andreasen, N. C., J. M. Azorin, R. L. Borison, W. T. Carpenter, G. Chouinard, L. J. Cohen, J. M. Davis, et al. “Current concepts in schizophrenia: International symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates.” Journal of Clinical Psychiatry 56, no. 5 (1995): 214–25.
    • Freudenreich, O., and J. P. McEvoy. “How much haldol D does Larry really need? [5].” Journal of Clinical Psychiatry 56, no. 7 (1995): 331–32.
    • Freudenreich, O., and J. P. McEvoy. “Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [4].” Journal of Clinical Psychiatry 56, no. 4 (1995): 173-.
    • Jr, C. L. S., W. A. Price, and J. P. McEvoy. “Effects of concomitant risperidone and lithium treatment [1].” American Journal of Psychiatry 152, no. 7 (1995): 1096-.
    • Hogarty, G. E., J. P. McEvoy, R. F. Ulrich, A. L. DiBarry, P. Bartone, S. Cooley, K. Hammill, M. Carter, M. R. Munetz, and J. Perel. “Pharmacotherapy of impaired affect in recovering schizophrenic patients.” Arch Gen Psychiatry 52, no. 1 (January 1995): 29. https://doi.org/10.1001/archpsyc.1995.03950130029004.
       Full Text  Link to Item
    • McEvoy, J. P. “Efficacy of risperidone on positive features of schizophrenia.” J Clin Psychiatry 55 Suppl (May 1994): 18–21.
       Link to Item
    • Burke, M. A., J. P. McEvoy, and J. C. Ritchie. “A pilot study of a structured interview addressing sexual function in men with schizophrenia.” Biol Psychiatry 35, no. 1 (January 1, 1994): 32–35. https://doi.org/10.1016/0006-3223(94)91164-9.
       Full Text  Link to Item
    • McEvoy, J. P., S. Freter, M. Merritt, and L. J. Apperson. “Insight about psychosis among outpatients with schizophrenia.” Hosp Community Psychiatry 44, no. 9 (September 1993): 883–84. https://doi.org/10.1176/ps.44.9.883.
       Full Text  Link to Item
    • McEvoy, J. P., G. Movin-Osswald, G. Uppfeldt, T. Williams, S. Dutcher, and J. Apperson. “An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients.” Psychopharmacology 112, no. 2–3 (1993): 371–74. https://doi.org/10.1007/BF02244935.
       Full Text
    • McEvoy, J. P., N. R. Schooler, E. Friedman, S. Steingard, and M. Allen. “Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight.” American Journal of Psychiatry 150, no. 11 (1993): 1649–53.
    • McEvoy, J. P. “Patients' rights.” Hosp Community Psychiatry 43, no. 4 (April 1992): 407. https://doi.org/10.1176/ps.43.4.407.
       Full Text  Link to Item
    • McEvoy, J. P., L. Kamaraju, and L. Nelson. “Haase hermeneutics, or, the exegesis of the neuroleptic threshold.” J Clin Psychopharmacol 12, no. 1 (February 1992): 64–65.
       Link to Item
    • McEvoy, J. P., G. E. Hogarty, and S. Steingard. “Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.” Arch Gen Psychiatry 48, no. 8 (August 1991): 739–45. https://doi.org/10.1001/archpsyc.1991.01810320063009.
       Full Text  Link to Item
    • McEvoy, J. P., N. R. Schooler, and W. H. Wilson. “Predictors of therapeutic response to haloperidol in acute schizophrenia.” Psychopharmacol Bull 27, no. 2 (1991): 97–101.
       Link to Item
    • Krystal, A. D., and J. P. McEvoy. “Shared features of neuroleptic malignant syndrome and alcohol abuse complications.” J Clin Psychiatry 51, no. 12 (December 1990): 523.
       Link to Item
    • Hammill, K., J. P. McEvoy, H. Koral, and N. Schneider. “Hospitalized schizophrenic patient views about seclusion.” J Clin Psychiatry 50, no. 5 (May 1989): 174–77.
       Link to Item
    • McEvoy, J. P., L. J. Apperson, P. S. Appelbaum, P. Ortlip, J. Brecosky, K. Hammill, J. L. Geller, and L. Roth. “Insight in schizophrenia. Its relationship to acute psychopathology.” Journal of Nervous and Mental Disease 177, no. 1 (1989): 43–47.
    • McEvoy, J. P., P. S. Applebaum, L. J. Apperson, J. L. Geller, and S. Freter. “Why must some schizophrenic patients be involuntarily committed? The role of insight.” Comprehensive Psychiatry 30, no. 1 (1989): 13–17.
    • McEvoy, J. P., S. Freter, G. Everett, J. L. Geller, P. Appelbaum, L. J. Apperson, and L. Roth. “Insight and the clinical outcome of schizophrenic patients.” Journal of Nervous and Mental Disease 177, no. 1 (1989): 48–51.
    • McEvoy, J. P., and S. Freter. “The dose-response relationship for memory impairment by anticholinergic drugs.” Comprehensive Psychiatry 30, no. 2 (1989): 135–38.
    • Hogarty, G. E., J. P. McEvoy, M. Munetz, A. L. DiBarry, P. Bartone, R. Cather, S. J. Cooley, R. F. Ulrich, M. Carter, and M. J. Madonia. “Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.” Archives of General Psychiatry 45, no. 9 (1988): 797–805.
    • McEvoy, J. P. “A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.” Journal of Clinical Psychiatry 48, no. SUPPL. SEP. (1987): 20–23.
    • McEvoy, J. P., M. McCue, B. Spring, R. C. Mohs, P. W. Lavori, and R. Farr. “The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers.” Psychopharmacology Bulletin 23, no. 1 (1987): 30–32.
    • McEvoy, J. P., M. McCue, B. Spring, R. C. Mohs, P. W. Lavori, and R. M. Farr. “Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers.” American Journal of Psychiatry 144, no. 5 (1987): 573–77.
    • McEvoy, J. P., R. L. Stiller, and G. R. Everett. “Differential therapeutic response by history during treatment with neuroleptic threshold haloperidol doses.” Journal of Clinical Psychopharmacology 7, no. 5 (1987): 368–69.
    • McEvoy, J. P., and G. M. Simpson. “Dystonia, neuroleptic dose, and anticholinergic drugs.” American Journal of Psychiatry 144, no. 3 (1987): 393–94.
    • McEvoy, J. P., M. McCue, and S. Freter. “Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.” Clinical Therapeutics 9, no. 4 (1987): 429–33.
    • Lake, C. R., D. E. Casey, J. P. McEvoy, S. G. Siris, W. F. Boyer, and G. Simpson. “Anticholinergic prophylaxis in young adults treated with neuroleptic drugs.” Psychopharmacology Bulletin 22, no. 3 (1986): 981–84.
    • McEvoy, J. P. “Neuroleptic dose and the need for prophylactic anticholinergic drugs.” Journal of Clinical Psychiatry 47, no. 12 (1986): 611-.
    • McEvoy, J. P. “The neuroleptic threshold as a marker of minimum effective neuroleptic dose.” Comprehensive Psychiatry 27, no. 4 (1986): 327–35.
    • McEvoy, J. P., R. L. Stiller, and R. Farr. “Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study.” Journal of Clinical Psychopharmacology 6, no. 3 (1986): 133–38.
    • McEvoy, J. P. “Rapid shifts in therapeutic and extrapyramidal effects of neuroleptics.” The American Journal of Psychiatry 143, no. 11 (1986): 1504-.
    • McEvoy, J. P. “Relief from catatonic immobility can be maintained.” Journal of Clinical Psychopharmacology 6, no. 2 (1986): 126–27.
    • McEvoy, J. P., A. C. Howe, and G. E. Hogarty. “Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients.” Journal of Nervous and Mental Disease 172, no. 7 (1984): 412–16.
    • McEvoy, J. P., and J. B. Lohr. “Diazepam for catatonia.” American Journal of Psychiatry 141, no. 2 (1984): 284–85.
    • McEvoy, J. P. “The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.” Journal of Clinical Psychopharmacology 3, no. 5 (1983): 288–302.
    • McEvoy, J. P., A. Hatcher, P. S. Appelbaum, and V. Abernethy. “Chronic schizophrenic women's attitudes toward sex, pregnancy, birth control, and childrearing.” Hospital and Community Psychiatry 34, no. 6 (1983): 536–39.
    • Guy, W., T. A. Ban, J. P. McEvoy, W. M. Petrie, W. H. Wilson, and J. D. Schaffer. “A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives.” International Pharmacopsychiatry 17, no. 1 (1982): 36–42.
    • McEvoy, J. P., W. H. Wilson, T. A. Ban, J. O. Brannen, and S. Berney. “Bromperidol maintenance in schizophrenia.” Pharmacopsychiatria 15, no. 3 (1982): 95–96.
    • Mcevoy, J. P., J. Libiger, W. H. Wilson, T. A. Ban, S. Berney, and W. Guy. “Viloxazine HCl in the treatment of endogenous depression: A standard (imipramine) controlled clinical study.” Journal of Clinical Psychiatry 43, no. 3 (1982): 111–12.
    • McEvoy, J. P., and V. Abernethy. “Sociocultural identity and psychogenic psychosis.” Papua and New Guinea Medical Journal 25, no. 1 (1982): 55–59.
    • Brannen, J. O., J. P. McEvoy, W. H. Wilson, W. M. Petrie, T. A. Ban, S. A. Berney, and J. D. Schaffer. “A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients.” Pharmacopsychiatria 14, no. 4 (1981): 139–40.
    • McEvoy, J. P. “Organic brain syndromes in DSM-III.” American Journal of Psychiatry 138, no. 1 (1981): 124–25.
    • McEvoy, J. P. “Organic brain syndromes.” Annals of Internal Medicine 95, no. 2 (1981): 212–20.
    • McEvoy, J. P., J. A. Jr, W. H. Wilson, W. Guy, and L. Hawkins. “Measuring chronic schizophrenic patients' attitudes toward their illness and treatment.” Hospital and Community Psychiatry 32, no. 12 (1981): 856–58.
    • McEvoy, J. P., S. Berney, W. H. Wilson, T. A. Ban, and W. Guy. “A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia.” International Pharmacopsychiatry 15, no. 5 (1980): 318–24.
    • McEvoy, J. P., W. F. Sheridan, and W. R. C. S. Jr. “Viloxazine in the treatmentof depressive neurosis: A controlled clinical study with doxepin and placebo.” British Journal of Psychiatry 137, no. 5 (1980): 440–43.
    • Petrie, W. M., J. P. McEvoy, W. H. Wilson, T. A. Ban, and W. Guy. “Viloxazine in the treatment of depressive neurosis: A placebo and standard (imipramine) controlled clinical study.” International Pharmacopsychiatry 15, no. 3 (1980): 193–96.
    • Ban, T. A., J. P. McEvoy, and W. H. Wilson. “Viloxazine: A review of the literature.” International Pharmacopsychiatry 15, no. 2 (1980): 118–23.
    • Ban, T. A., W. H. Wilson, and J. P. McEvoy. “Amoxapine: A review of literature.” International Pharmacopsychiatry 15, no. 3 (1980): 166–70.
    • McEvoy, J. P., and C. E. Wells. “Case studies in neuropsychiatry II: Conversion pseudodementia.” Journal of Clinical Psychiatry 40, no. 10 (1979): 447–49.
    • McEvoy, J. P. “Psychiatric consultations.” Southern Medical Journal 71, no. 11 (1978): 1321–22.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.